MedPath

The effect of combination therapy with Alendronate and Eldecalcitol for glucocorticoid induced osteoporosis -switch from Alfacalcidol to Eldecalcitol

Not Applicable
Conditions
glucocorticoid induced osteoporosis
Registration Number
JPRN-UMIN000009588
Lead Sponsor
Department of Rheumatic Disease, Shinko Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with contraindication for Eldecalcitol treatments 2. Patients who are inappropriate for this study by physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change from baseline to 12 months in lumbar spine BMD
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath